RESPeRATE Device in Reducing Anxiety in Early-Stage Lung Cancer Survivors

Inclusion Criteria

• Past history of any lung cancer
• For stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of disease
• For stage IV disease, patients may be receiving no treatment or may be receiving maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the most recent imaging does not demonstrate progressive disease
• After completion of all three screening questionnaires, participant must score accordingly on at least one questionnaire to be eligible: * Score >= 8 on the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS)-Anxiety/Depression Scale OR * Score >= 4 on the Distress Thermometer OR * Score > 5 on the Modified Cancer Acceptance Scale
• Eastern Cooperative Oncology Group performance status 0-2
• Willing/able to attend brief introductory session and use assigned device for the assigned period of time (15 minutes once or twice per day), at least 5 days per week for 12 weeks
• Must have telephone

Exclusion Criteria

• Patient does not understand English
• Active lung infection
• Progressive cancer (must be considered no evidence of disease or stable)
• Any change in psychotropic medications in past 30 days
• Hearing loss that would preclude participating in interventions; adequate hearing to participate will be determined via: (1) response of “no” to the question [“Do you have a hearing problem now?”]; participants with hearing aids will be allowed to enroll as long as their hearing is adequate to hear the sounds on the study devices; if necessary, potential study participants will receive a brief test trial with the RESPeRATE device; if they indicate inability to hear the guiding tones, they will not be enrolled in the study
• CORTISOL EXCLUSION: Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on steroid-based medications are excluded from the cortisol portion of the study (with the exception of topical hydrocortisone that is permitted)